Patents Represented by Attorney, Agent or Law Firm David L. Rose
  • Patent number: 7205292
    Abstract: The present invention is directed to compounds of Formula I and Formula II: (where variables R1, R2, R3, R4, R6, A, B, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: April 17, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Christopher S. Burgey, Daniel V. Paone, Anthony W. Shaw, Theresa M. Williams
  • Patent number: 7205293
    Abstract: The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: April 17, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Ian M. Bell, Samuel L. Graham, Theresa M. Williams, Craig A. Stump
  • Patent number: 7202251
    Abstract: The present invention is directed to compounds of the formula: that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: April 10, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Ian M. Bell, Steven N. Gallicchio, Cory R. Theberge, Xu-Fang Zhang, Craig Stump, C. Blair Zartman
  • Patent number: 7196079
    Abstract: The present invention is directed to compounds of Formula I: (where variables R1, R2, R3, R6, R7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: March 27, 2007
    Assignee: Merck & Co, Inc.
    Inventors: Christopher S. Burgey, Craig A. Stump, Theresa M. Williams
  • Patent number: 7192954
    Abstract: The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: March 20, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Ian M. Bell, Cory R. Theberge, Theresa M. Williams, C. Blair Zartman, Xu-Fang Zhang, Steven N. Gallicchio
  • Patent number: 7189722
    Abstract: The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: March 13, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Ian M. Bell, Cory R. Theberge, Xu-Fang Zhang, C. Blair Zartman
  • Patent number: 7163951
    Abstract: N-Biarylmethylaminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Grant
    Filed: August 25, 2003
    Date of Patent: January 16, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Scott D. Kuduk, Michael R. Wood, Mark G. Bock
  • Patent number: 7144913
    Abstract: Dihydropyrroloindoles and tetrahydropyridoindoles are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: December 5, 2006
    Assignee: Merck Frosst Canada & Co.
    Inventors: Zhaoyin Wang, Christian Beaulieu, Claude Dufresne, Daniel Guay, Yves LeBlanc
  • Patent number: 7105533
    Abstract: Phenyl compounds substituted with a fused-heterobicyclo moiety, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
    Type: Grant
    Filed: September 9, 2003
    Date of Patent: September 12, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Brian Thomas Campbell, Janet Lorraine Gunzer, Benito Munoz, Brian Andrew Stearns, Jean-Michel Andre Vernier, Bowei Wang
  • Patent number: 7091380
    Abstract: N-Biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: August 15, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Michael R. Wood, Neville J. Anthony, Mark G. Bock, Dong-Mei Feng, Scott D. Kuduk, Dai-Shi Su, Jenny Miu-chun Wai
  • Patent number: 7087601
    Abstract: Phenyl compounds substituted at the 1-position with a fused bicyclo moeity formed from a five-membered heterocycle fused to a six-membered carbocycle, to a six-membered aryl, or to a six-membered hetaryl, and further optionally substituted at the 3,4 positions, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: August 8, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Jeannie Arruda, Celine Bonnefous, Brian T. Campbell, Rowena V. Cube, Benito Munoz, Brian Stearns, Jean-Michel Vernier, Bowei Wang, Xiumin Zhao
  • Patent number: 6835837
    Abstract: A substituted 8-aryl quinoline and its benzenesulfonic acid salt is synthesized.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: December 28, 2004
    Assignee: Merck & Co. Inc.
    Inventors: Richard Desmond, David A. Conlon, Antoinette Drahus, Guo-Jie Ho, Brenda Pipik, Carl Leblond, Anant Vailaya
  • Patent number: 6812234
    Abstract: The present invention is directed to compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.
    Type: Grant
    Filed: April 29, 2003
    Date of Patent: November 2, 2004
    Assignees: Merck & Co., Inc., Merck Sharp & Dohme Ltd.
    Inventors: Richard Jiao, Gregori Morriello, Lihu Yang, Stephen D. Goble, Sander G. Mills, Alexander Pasternak, Changyou Zhou, Gabor Butora, Shankaran Kothandaraman, Deodialsingh Guiadeen, Christopher Moyes, Cheng Tang
  • Patent number: 6812346
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: November 2, 2004
    Assignee: Merck Frosst Canada and Co.
    Inventors: Daniel Dube, Rejean Fortin, Richard Friesen
  • Patent number: 6809199
    Abstract: Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof: are inhibitors of p38 useful in the treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: October 26, 2004
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, John E. Stelmach, Meng-Hsin Chen, Luping Liu, Julianne A. Hunt, Rowena D. Ruzck, Joung L. Goulet, David D. Wisnoski, Swaminathan Ravi Natarajan, Kathleen M. Rupprecht, Jianming Bao, Shouwu Miao, Xingfang Hong, Peter J. Sinclair, Florida Kallashi
  • Patent number: 6800647
    Abstract: This invention encompasses a pharmaceutical composition comprising the compound of formula A: in combination with a pharmaceutically acceptable carrier, said compound being comprised of about 1-50%, 1-20% or 1-10% of the polymorphic form which is designated Form V and the remainder of the compound being comprised of at least one polymorphic form selected from the group consisting of: Form I, Form II, Form III and Form IV.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: October 5, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Loius S. Crocker, Ian W. Davies, Richard G. Osifchin, Andrew Kotliar
  • Patent number: 6774138
    Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: August 10, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas David Peter Cosford, Leo Solomon Bleicher, Jean-Michel Andre Vernier, Rowena V. Cube, Edwin Schweiger, Ian McDonald
  • Patent number: 6767908
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which may be useful for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: July 27, 2004
    Assignee: Merck & Co., Inc
    Inventors: Christopher F. Claiborne, Nigel J. Liverton, David A. Claremon
  • Patent number: 6743802
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: June 1, 2004
    Assignee: Merck Frosst Canada & Co.
    Inventors: Daniel Guay, Mario Girard, Pierre Hamel, Sebastien Laliberte, Richard Friesen
  • Patent number: 6740666
    Abstract: Novel sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, 2-naphthalenesulfonic acid, hydrochloride acid, or benzenesulfonic acid salts of substituted 8-arylquinolines, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, are PDE4 inhibitors.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: May 25, 2004
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Dwight Macdonald, Helene Perrier, Roch Thibert, Guo-Jie Ho, Anant Vailaya, David Conlon, Elizabeth Kwong, Sophie-Dorothee Clas